From L-R: Arda Therapeutics chief technology officer Remi-Martin Laberge, CEO Adam Freund and CSO Scott Turner
Exclusive: Lilly backs a16z-funded Arda Therapeutics' $43M Series A to take ADCs into fibrosis
A three-year-old startup based on decades of research in cell depletion is betting that some of the hottest tools in oncology may work even better …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.